Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges

Blood Cancer Discov. 2025 May 5;6(3):159-162. doi: 10.1158/2643-3230.BCD-23-0240.

Abstract

Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this report, we highlight steps toward unlocking this potential, including the need for standardized, comprehensive data repositories as a way for addressing barriers to artificial intelligence learning, such as data heterogeneity and patient privacy.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence*
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen